STOCKHOLM, SWEDEN / ACCESSWIRE / December 21, 2023 / Promore Pharma (STO:PROMO) (FRA:8T0) Promore Pharma AB (publ), under name change to PMD Device Solutions AB (the 'Company'), has received approval for continued trading on Nasdaq First North Growth Market and publishes a company description prepared in connection with the name and business change of the Company as a result of the planned acquisition of PMD Device Solutions AB..

瑞典斯德哥尔摩/ACCESSWIRE/2023年12月21日/Promore Pharma（STO：PROMO）（FRA：8T0）Promore Pharma AB（publ），更名为PMD Device Solutions AB（“公司”），已获得在纳斯达克第一北方增长市场（Nasdaq First North Growth Market）继续交易的批准，并发布了一份公司描述，该公司因计划收购PMD Device Solutions AB而发生名称和业务变更。。

On 29 November 2023, the Company announced the reverse acquisition of PMD Device Solutions AB, subject to resolution by the extraordinary general meeting of the Company on 29 December 2023 (the 'Reverse Acquisition'). The Company has today received approval from Nasdaq Stockholm for continued trading on Nasdaq First North Growth Market, subject to customary conditions.

2023年11月29日，公司宣布反向收购PMD Device Solutions AB，但须经2023年12月29日公司临时股东大会决议（“反向收购”）。该公司今天已获得纳斯达克斯德哥尔摩公司的批准，可根据惯例条件在纳斯达克第一北方增长市场继续交易。

The Company also publishes a company description due to the Reverse Acquisition and the continued listing. The company description is available at www.promorepharma.com..

由于反向收购和继续上市，该公司还发布了公司描述。公司简介可从www.promorepharma.com获得。。

Information about PMD

PMD信息

PMD develops and sells medical products for respiratory monitoring. Its primary product is RespiraSense™, a solution used for monitoring respiratory rate to detect deterioration of a patient's general condition early and to avoid preventable respiratory failure and adverse patient outcomes. RespiraSense™ is, to the PMD's knowledge, the world's only continuous, motion-tolerant respiratory rate monitor delivering class-leading reliability in measuring respiratory rate.

PMD开发和销售用于呼吸监测的医疗产品。它的主要产品是呼吸感应™,一种用于监测呼吸频率的解决方案，以尽早发现患者一般状况的恶化，并避免可预防的呼吸衰竭和患者不良后果。呼吸感应™据PMD所知，它是世界上唯一一款连续、耐运动的呼吸频率监测仪，在测量呼吸频率方面具有一流的可靠性。

PMD received FDA approval for RespiraSense™ in 2022. RespiraSense™ is a novel technology and today used in 25 hospitals across United Kingdom and Ireland. PMD seeks to continue increasing its market share in the United Kingdom, with Germany and the United States to follow with initial market access activities..

PMD获得FDA对RespiraSense的批准™2022年。呼吸感应™是一项新技术，目前已在英国和爱尔兰的25家医院使用。PMD寻求继续增加其在英国的市场份额，德国和美国将跟进最初的市场准入活动。。

For additional information, please contact:

有关更多信息，请联系：

Lars-Henrik Andersson, liquidator

Lars Henrik Andersson，清算人

Phone: [+46] 8 527 91 600

电话：[+46]8 527 91 600

E-mail: Lars-Henrik.Andersson@cirio.se

电子邮件：lars-henrik.andersson@cirio.se

Promore Pharma's Certified Adviser is Redeye

Promore Pharma的认证顾问是Redeye

Promore Pharma in brief

Promore Pharma在信中

Promore Pharma is a biopharmaceutical company specialized in the development of locally administered first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. The company is listed on Nasdaq First North Growth Market..

Promore Pharma是一家生物制药公司，专门开发当地管理的一流药物，用于满足高度未满足的医疗需求，其中有效的处方药很少。该公司在纳斯达克第一北方增长市场上市。。

Attachments

附件

Promore Pharma AB (publ) has received approval for continued trading on Nasdaq First North Growth Market and publishes company description

Promore Pharma AB（publ）已获得在纳斯达克第一北方增长市场继续交易的批准，并发布了公司描述

SOURCE: Promore Pharma

来源：Promore Pharma

View the original press release on accesswire.com

在accesswire.com上查看原始新闻稿